FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2333245346> ?p ?o ?g. }

• W2333245346 abstract "Extensive-disease small-cell lung cancer (ED-SCLC) is characterized by rapid progression and relapse, despite high initial response rates to chemotherapy. The primary objective of this trial was to demonstrate the non-inferiority of amrubicin and cisplatin (AP) combination therapy compared with the standard first-line regimen of etoposide and cisplatin (EP) for previously untreated ED-SCLC in a Chinese population. When non-inferiority was verified, the objective was switched from non-inferiority to superiority.From June 2008 to July 2010, 300 patients were enrolled and randomly assigned at a 1:1 ratio to AP and EP groups. AP-treated patients received cisplatin (60 mg/m(2), day 1) and amrubicin (40 mg/m(2), days 1-3) once every 21 days. EP-treated patients received cisplatin (80 mg/m(2), day 1) and etoposide (100 mg/m(2), days 1-3) once every 21 days. Treatment was continued for four to six cycles, except in cases of progressive disease or toxicity, and patient refusal.Median overall survival (OS) for AP vs. EP treatment was 11.8 vs. 10.3 months (p = 0.08), respectively, demonstrating non-inferiority of AP to EP (AP group: 95% confidence interval for hazard ratio 0.63-1.03 months). Median progression-free survival and overall response rates for AP vs. EP groups were 6.8 vs. 5.7 months (p = 0.35) and 69.8% vs. 57.3%, respectively. Drug-related adverse events in both groups were similar, with neutropenia being the most frequent (AP 54.4%; EP 44.0%). Leukopenia, pyrexia, and fatigue were more prevalent in the AP group, but all were clinically reversible and manageable.AP therapy demonstrated non-inferiority to EP therapy, prolonging OS for 1.5 months, but this difference was not statistically significant; thus we propose AP as a promising treatment option for ED-SCLC in China.This trial was registered on 10 April 2008 (ClinicalTrials.gov NCT00660504)." @default.
• W2333245346 created "2016-06-24" @default.
• W2333245346 creator A5000374825 @default.
• W2333245346 creator A5000432967 @default.
• W2333245346 creator A5002096737 @default.
• W2333245346 creator A5002652167 @default.
• W2333245346 creator A5009866828 @default.
• W2333245346 creator A5021139793 @default.
• W2333245346 creator A5023128001 @default.
• W2333245346 creator A5028386179 @default.
• W2333245346 creator A5032749176 @default.
• W2333245346 creator A5043672686 @default.
• W2333245346 creator A5048001385 @default.
• W2333245346 creator A5057704753 @default.
• W2333245346 creator A5063300954 @default.
• W2333245346 creator A5066716873 @default.
• W2333245346 creator A5067152089 @default.
• W2333245346 creator A5072522693 @default.
• W2333245346 creator A5075877965 @default.
• W2333245346 creator A5077884718 @default.
• W2333245346 creator A5083147929 @default.
• W2333245346 date "2016-04-09" @default.
• W2333245346 modified "2023-10-12" @default.
• W2333245346 title "Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer" @default.
• W2333245346 cites W1495781375 @default.
• W2333245346 cites W1898563448 @default.
• W2333245346 cites W1966767452 @default.
• W2333245346 cites W1971264126 @default.
• W2333245346 cites W1973931044 @default.
• W2333245346 cites W1982393289 @default.
• W2333245346 cites W2000366267 @default.
• W2333245346 cites W2054935156 @default.
• W2333245346 cites W2065188377 @default.
• W2333245346 cites W2073683299 @default.
• W2333245346 cites W2080034179 @default.
• W2333245346 cites W2094528202 @default.
• W2333245346 cites W2108113897 @default.
• W2333245346 cites W2108882850 @default.
• W2333245346 cites W2114699219 @default.
• W2333245346 cites W211855203 @default.
• W2333245346 cites W2120435735 @default.
• W2333245346 cites W2129000805 @default.
• W2333245346 cites W2133266907 @default.
• W2333245346 cites W2142089984 @default.
• W2333245346 cites W2155723257 @default.
• W2333245346 cites W2164922431 @default.
• W2333245346 cites W2166418266 @default.
• W2333245346 cites W2167746331 @default.
• W2333245346 cites W2168920995 @default.
• W2333245346 cites W2170260373 @default.
• W2333245346 cites W2200433921 @default.
• W2333245346 cites W2566863750 @default.
• W2333245346 cites W332202582 @default.
• W2333245346 doi "https://doi.org/10.1186/s12885-016-2301-6" @default.
• W2333245346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826513" @default.
• W2333245346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27061082" @default.
• W2333245346 hasPublicationYear "2016" @default.
• W2333245346 type Work @default.
• W2333245346 sameAs 2333245346 @default.
• W2333245346 citedByCount "32" @default.
• W2333245346 countsByYear W23332453462016 @default.
• W2333245346 countsByYear W23332453462017 @default.
• W2333245346 countsByYear W23332453462018 @default.
• W2333245346 countsByYear W23332453462019 @default.
• W2333245346 countsByYear W23332453462020 @default.
• W2333245346 countsByYear W23332453462021 @default.
• W2333245346 countsByYear W23332453462022 @default.
• W2333245346 countsByYear W23332453462023 @default.
• W2333245346 crossrefType "journal-article" @default.
• W2333245346 hasAuthorship W2333245346A5000374825 @default.
• W2333245346 hasAuthorship W2333245346A5000432967 @default.
• W2333245346 hasAuthorship W2333245346A5002096737 @default.
• W2333245346 hasAuthorship W2333245346A5002652167 @default.
• W2333245346 hasAuthorship W2333245346A5009866828 @default.
• W2333245346 hasAuthorship W2333245346A5021139793 @default.
• W2333245346 hasAuthorship W2333245346A5023128001 @default.
• W2333245346 hasAuthorship W2333245346A5028386179 @default.
• W2333245346 hasAuthorship W2333245346A5032749176 @default.
• W2333245346 hasAuthorship W2333245346A5043672686 @default.
• W2333245346 hasAuthorship W2333245346A5048001385 @default.
• W2333245346 hasAuthorship W2333245346A5057704753 @default.
• W2333245346 hasAuthorship W2333245346A5063300954 @default.
• W2333245346 hasAuthorship W2333245346A5066716873 @default.
• W2333245346 hasAuthorship W2333245346A5067152089 @default.
• W2333245346 hasAuthorship W2333245346A5072522693 @default.
• W2333245346 hasAuthorship W2333245346A5075877965 @default.
• W2333245346 hasAuthorship W2333245346A5077884718 @default.
• W2333245346 hasAuthorship W2333245346A5083147929 @default.
• W2333245346 hasBestOaLocation W23332453461 @default.
• W2333245346 hasConcept C126322002 @default.
• W2333245346 hasConcept C141071460 @default.
• W2333245346 hasConcept C143998085 @default.
• W2333245346 hasConcept C207103383 @default.
• W2333245346 hasConcept C2776256026 @default.
• W2333245346 hasConcept C2776694085 @default.
• W2333245346 hasConcept C2777063308 @default.
• W2333245346 hasConcept C2778119113 @default.
• W2333245346 hasConcept C2778239845 @default.
• W2333245346 hasConcept C2778850193 @default.
• W2333245346 hasConcept C2780739268 @default.

• next